Your BelloBella clinician reviews how you are responding to each dose level during scheduled appointments
In this study, we studied patients with overweight or obesity initiating either semaglutide or tirzepatide between May 2022 and September 2023
Ishy PL et al, Acta Psychiatr Scand 2017;136(1):5262)
It was first developed as a treatment for type 2 diabetes, but it has also become popular for weight loss in people who do not have diabetes
Per the systematic review of 118 trials, the effect is "moderate but meaningful", which means it's not a magic bullet, but it significantly improves outcomes, especially for the heavy-drinking pattern that causes most of the harm
00:00:46 Narrator None of the speakers have anything to disclose